Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain

Roivant Sciences

20/05/2026 12:08

Overview

Switzerland-based biopharma firm reported Q4 income from operations beat analyst expectations

Q4 net income swung positive, aided by $770 mln gain from Moderna litigation settlement

Q4 R&D expenses rose, mainly due to program-specific costs and batoclimab discontinuation

Outlook

Company expects to launch brepocitinib in dermatomyositis by end of September 2026

Roivant anticipates topline Phase 3 data for brepocitinib in non-infectious uveitis in H2 2026

Company expects topline data from mosliciguat Phase 2 PHocus study in PH-ILD in H2 2026

Result Drivers

LITIGATION SETTLEMENT - Q4 results benefited from a $770 mln gain related to the Moderna settlement

HIGHER R&D SPENDING - R&D expenses rose due to increased program-specific costs, including anti-FcRn franchise and batoclimab discontinuation

INCREASED G&A COSTS - General and administrative expenses rose, mainly due to higher personnel-related costs, professional fees, and share-based compensation

Company press release: ID:nGNX7PbLww

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$2.52 mln
Q4 EPS
$0.28
Q4 Net Income
$355.74 mln
Q4 Income From Operations
Beat
$415.24 mln
-$310.39 mln (8 Analysts)
Q4 Operating Expenses
$357.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Roivant Sciences Ltd is $35.00, about 24.1% above its May 19 closing price of $28.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)